S-637880

S-637880 is an orally bioavailable small molecule antagonist of the P2X7 receptor, developed by Shionogi & Co., Ltd. for the treatment of neuropathic pain. The P2X7 receptor is an ATP-gated ion channel primarily expressed on microglia and other immune cells; its activation triggers the release of pro-inflammatory cytokines such as IL-1β and IL-18, which are key mediators in the development and maintenance of chronic neuropathic pain. S-637880 was evaluated in a Phase 2a clinical trial in Japan specifically for patients with neuropathic low back pain. However, the trial was prematurely terminated at all sites, and the development of the compound for this indication has since been discontinued by the sponsor.